Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.54 - $9.89 $2,270 - $4,945
-500 Reduced 7.94%
5,800 $29,000
Q1 2024

May 15, 2024

BUY
$4.03 - $8.13 $22,165 - $44,715
5,500 Added 687.5%
6,300 $51,000
Q4 2023

Feb 14, 2024

BUY
$3.56 - $4.65 $2,492 - $3,255
700 Added 700.0%
800 $3,000
Q3 2023

Nov 14, 2023

SELL
$4.02 - $5.81 $7,235 - $10,458
-1,800 Reduced 94.74%
100 $0
Q2 2023

Aug 14, 2023

BUY
$3.06 - $6.38 $5,814 - $12,122
1,900 New
1,900 $11,000
Q4 2022

Feb 14, 2023

BUY
$3.03 - $3.79 $5,757 - $7,201
1,900 New
1,900 $6,000

Others Institutions Holding XBIT

About XBiotech Inc.


  • Ticker XBIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,439,300
  • Market Cap $203M
  • Description
  • XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...
More about XBIT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.